Laham Y, Ringelstein-Harlev S, Kurnik D, Fineman R, Yehudai-Ofir D, Bonstein L, Setter-Marco N, Braun E, Ghersin I, Zuckerman T, Beyar-Katz O. High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies. Haematologica; https://doi.org/10.3324/haematol.2024.286714 [Early view].